Rhythm Pharmaceuticals

Yahoo Finance • 2 days ago

Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026

-- Setmelanotide therapy achieved robust, sustained and clinically significant weight loss in patients with acquired HO at 2.5 years -- -- Bivamelagon therapy achieved progressive reductions in BMI and hunger measures in patients (N=26) w... Full story

Yahoo Finance • 4 days ago

 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures -- --... Full story

Yahoo Finance • 5 days ago

Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome

BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today anno... Full story

Yahoo Finance • last month

Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday

Key Points The biotech was in the headlines recently after the FDA approved a new indication for its single commercialized drug. There might be more where that came from with Imcivree.10 stocks we like better than Rhythm Pharmaceuticals ›... Full story

Yahoo Finance • 2 months ago

Rhythm Pharmaceuticals (RYTM): Precision Obesity Pivot Grabs Headlines

We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) ranks 5th on this list. While Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) faces high cash burn, hedge fu... Full story

Yahoo Finance • 2 months ago

Rhythm Pharmaceuticals Announces Changes to Board of Directors

-- Kim Popovits appointed as new Director; Ed Mathers to depart -- BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the l... Full story

Yahoo Finance • 3 months ago

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment

-- European Commission decision anticipated in second quarter of 2026 -- BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming... Full story

Yahoo Finance • 3 months ago

Rhythm Grabs A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat'

Rhythm Pharmaceuticals stock ultimately closed down Friday, though the FDA signed off on its drug, Imcivree, for a genetic form of obesity. Continue Reading... Full story

Yahoo Finance • 3 months ago

Stocks Fall on Spillover Effects from Iran War

The S&P 500 Index ($SPX) (SPY) today is down -0.88%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.59%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -1.22%.  March E-mini S&P futures (ESM26) are down -0.95%, and March E-mini... Full story

Yahoo Finance • 3 months ago

Rhythm Pharmaceuticals (RYTM) Reports Phase 3 EMANATE Trial Topline Results for Setmelanotide

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) is one of the most promising stocks under $100 to buy. On March 16, Rhythm Pharmaceuticals announced topline results from its global Phase 3 EMANATE trial, which evaluated the efficacy of setmelano... Full story

Yahoo Finance • 3 months ago

Rhythm Surges On A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat'

Rhythm Pharmaceuticals stock popped Friday after the FDA signed off on its obesity drug for patients with a rare, hunger-spiking disease. Continue Reading... Full story

Yahoo Finance • 3 months ago

Rhythm Secures FDA Approval For IMCIVREE In Acquired Hypothalamic Obesity

(RTTNews) - Rhythm Pharmaceuticals, Inc. (RYTM) announced that the FDA has approved IMCIVREE for the treatment of acquired hypothalamic obesity, marking the first and only therapy cleared for this rare and severe condition. Acquired hypot... Full story

Yahoo Finance • 3 months ago

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

-- First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfunction – -- Indicated to reduce excess... Full story

Yahoo Finance • 3 months ago

Rhythm Pharmaceuticals (RYTM) PT Increased From $136 to $143 at Wells Fargo on IMCIVREE Launch Optimism

We recently compiled a list of the Top 10 Boring Stocks That Make Money. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is one of the most boring stocks that make money. TheFly reported on March 12 that Wells Fargo increased its price target... Full story

Yahoo Finance • 3 months ago

Rhythm's EMANATE Trial Misses Endpoint But Shows BMI Reductions

(RTTNews) - Rhythm Pharmaceuticals, Inc. (RYTM) has announced topline results from its global Phase 3 EMANATE trial of Setmelanotide, an MC4R agonist designed to address rare, genetically driven forms of obesity. While the four sub studie... Full story

Yahoo Finance • 3 months ago

Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing

On February 17, 2026, Opaleye Management Inc. reported selling out its entire stake in Immunome(NASDAQ:IMNM), an estimated $37.30 million trade based on quarterly average pricing. What Happened According to its SEC filing dated February... Full story

Yahoo Finance • 3 months ago

Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing

Opaleye Management Inc. disclosed in a February 17, 2026, SEC filing that it sold 180,000 shares of Liquidia(NASDAQ:LQDA), an estimated $5.12 million trade based on quarterly average pricing. What Happened According to a SEC filing dated... Full story

Yahoo Finance • 3 months ago

Rhythm Pharmaceuticals price target lowered to $110 from $125 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $110 from $125 and keeps a Buy rating on the shares, reflecting adjustments to the firm’s long-term sales ramp expectations after Rhythm recently announced... Full story

Yahoo Finance • 4 months ago

Notable Two Hundred Day Moving Average Cross - RYTM

In trading on Friday, shares of Rhythm Pharmaceuticals Inc (Symbol: RYTM) crossed below their 200 day moving average of $93.81, changing hands as low as $91.52 per share. Rhythm Pharmaceuticals Inc shares are currently trading off about 5... Full story

Yahoo Finance • 4 months ago

Rhythm anticipates $385M–$415M in 2026 non-GAAP operating expenses as HO launch preparations accelerate

Earnings Call Insights: Rhythm Pharmaceuticals (RYTM) Q4 2025 MANAGEMENT VIEW * CEO David Meeker highlighted the continued strong performance of Rhythm’s commercial teams, noting, "The BBS opportunity continues to grow at a steady rate... Full story